Dr Agarwal’s Health Care: NCLT Merger Vote on July 2, 2026

Share price and why the dates matter

Dr Agarwal’s Health Care share price was ₹470.05 as of 2 Jul, 2026. The stock is now in focus because the company has scheduled NCLT-convened meetings of equity shareholders and unsecured creditors on July 02, 2026. These meetings are meant to vote on a proposed Scheme of Amalgamation with Dr. Agarwal’s Eye Hospital Limited. The exercise is procedural, but it is a key checkpoint because the scheme cannot move forward without the required approvals. The company has formally notified stakeholders about these NCLT-directed meetings. Investors tracking corporate actions are watching for the voting outcome and the next step at the tribunal.

What the proposed amalgamation is

If the scheme is approved by the stakeholders and subsequently by the NCLT, Dr. Agarwal’s Eye Hospital Limited will be amalgamated into Dr. Agarwals Health Care Limited. In practical terms, this would mean the transferor entity (the eye hospital company) would merge into the listed company, subject to approvals. The communications provided describe this as part of a plan to simplify the group’s corporate structure. The meetings are structured separately for equity shareholders and unsecured creditors, reflecting the statutory process under the Companies Act. The NCLT’s directions set the framework for how the voting must be conducted and recorded. Any final effect depends on tribunal sanction after stakeholder voting.

NCLT Chennai Bench order and legal basis

The Chennai Bench of the National Company Law Tribunal allowed the first motion application for the proposed amalgamation and directed the convening of meetings. The order was passed by a bench comprising Judicial Member Sanjiv Jain and Technical Member Venkataraman Subramaniam. The application was filed under Sections 230 to 232 of the Companies Act, 2013. The order was pronounced on May 05, 2026, and uploaded on May 11, 2026. The case is recorded as CA(CAA)/19(CHE)/2026 with citation 2026 LLBiz NCLT(CHE) 449. The order provides a formal venue for shareholders and creditors to approve or reject the scheme.

Meeting schedule, venue, and who votes

The meetings are scheduled for Thursday, July 02, 2026, in Chennai. The notice states the venue as The Music Academy, Chennai. Separate sessions are planned for different stakeholder classes, reflecting the NCLT-directed structure. Equity shareholders are scheduled to meet at 12:30 PM IST. Unsecured creditors are scheduled to meet at 4:00 PM IST. The company has also indicated that physical attendance is an option for the July 2 meetings. The notice is available on the websites of BSE Limited and the National Stock Exchange of India Limited.

Remote e-voting window and how notices were sent

Remote e-voting has been arranged as part of the process. Physical notices with web-links and QR codes were dispatched to facilitate remote e-voting. The remote e-voting period runs from June 07, 2026 at 9:00 AM IST to July 01, 2026 at 5:00 PM IST. For unsecured creditors, the notice mentions that electronic voting credentials, including the EVEN (E Voting Event Number), User ID, and Password or PIN, are provided in a table within the notice. Stakeholders are directed to follow instructions for voting through NSDL’s e-voting facility or use polling papers at the meeting. For queries or assistance on KYC updation or to obtain a physical copy of the notice, holders are asked to contact their Depository Participants or the company at [email protected].

Cut-off dates for eligibility

The notice lays out multiple cut-off dates connected to dispatch and e-voting eligibility. Key dates include a cut-off date of May 22, 2026, for sending the notice and June 03, 2026, for determining e-voting eligibility. Separately, for unsecured creditors, the cut-off date for sending the notice and determining eligibility for e-voting is stated as December 31, 2025. These dates matter because they determine which stakeholders can vote using the electronic process. They also set the administrative record used for the meeting and voting reconciliation. Investors typically track cut-off dates to understand whether their holdings qualify for participation. The company’s communication emphasizes careful review of instructions ahead of voting.

What happens if approvals do not come through

The scheme requires stakeholder approval and then NCLT approval to proceed. The notice indicates that failure to obtain the required majority vote from either equity shareholders or unsecured creditors could halt the amalgamation process. This is a standard safeguard in tribunal-supervised schemes because different classes must separately approve the arrangement. If approvals are received at the meetings, the matter moves to the next stage where the NCLT considers whether to sanction the scheme. The company has not provided an outcome in the provided material, only the process and schedule. Investors are advised in the notice to monitor announcements regarding the voting results and subsequent NCLT approval or rejection. Any decision at the tribunal would be a separate step after the stakeholder vote.

Recent financial performance disclosed by the company

Alongside the corporate action, the company has also reported financial performance figures that investors may track as context. For Q4FY26, total income stood at ₹577 crore, a YoY growth of 21.2% from ₹476 crore in Q4FY25 and a QoQ growth of 6.77% from ₹540.40 crore in Q3FY26. For FY26, total income reached ₹2,125 crore, up 20.9% YoY from ₹1,757 crore in FY25. Revenue from operations in Q4FY26 was ₹564.11 crore, up 22.57% YoY from ₹460.22 crore and up 6.46% QoQ from ₹529.86 crore. Profit after tax for Q4FY26 was ₹50 crore, up 17.4% YoY from ₹43 crore and up 14.51% QoQ from ₹43.63 crore. For FY26, PAT rose 52.4% YoY to ₹168 crore versus ₹110 crore in FY25, while annual basic EPS for FY26 was ₹4.21 compared with ₹2.80 in FY25.

Key facts at a glance

Financial snapshot (INR crore)

Market impact and what investors should track next

The immediate market relevance is event-driven, because the meetings determine whether the scheme progresses to the next stage. The company has highlighted that the outcome of the July 2 voting and any subsequent NCLT decision will be critical. From an operational perspective, the NCLT process provides a structured route to consolidate entities, but it is dependent on stakeholder majorities and tribunal approval. For investors, the practical checklist is straightforward: confirm whether the scheme receives approvals from equity shareholders and unsecured creditors, and then track the company’s next disclosure on NCLT proceedings. The notice also points investors to exchange websites, which is typically where formal updates are published.

Conclusion

Dr Agarwal’s Health Care is at a defined procedural milestone, with NCLT-convened meetings on July 02, 2026 to vote on amalgamating Dr. Agarwal’s Eye Hospital into the listed entity. Remote e-voting is open from June 07 to July 01, 2026, and physical attendance is allowed at the Chennai meetings. The next concrete updates will be the voting outcome and any follow-up filing or order from the NCLT on whether the scheme is approved or rejected.